Israel Healthcare Ventures

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

Lifeward is a medical device company based in Marlborough, Massachusetts, specializing in innovative solutions for individuals with lower limb disabilities. The company develops, manufactures, and markets advanced walking systems, notably the ReWalk Rehabilitation System and the ReWalk Personal System. The ReWalk Rehabilitation System is designed for use in rehabilitation centers, enabling users to walk, stand, sit, and navigate stairs. In contrast, the ReWalk Personal System is intended for everyday use, allowing individuals to engage in activities at home, work, and various outdoor environments. This system supports standing, sitting, and turning, while also facilitating stair climbing and descending. Lifeward's mission is to enhance the quality of life for those with spinal cord injuries by providing robotic technologies that offer significant functional and health benefits across different settings, including clinical environments and everyday life. The company operates primarily in the United States and Europe, with additional sales in Asia, the Middle East, and South America.

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

OrSense Ltd. is a medical device company based in Petah-Tikva, Israel, founded in 1996. The company specializes in developing and marketing non-invasive monitoring technologies for measuring various blood parameters. Its flagship product, the NBM 200 system, enables continuous monitoring of blood hemoglobin levels, oxygen saturation, and pulse rate without the need for invasive procedures. The NBM 200MP further enhances this capability by measuring multiple blood parameters, including hematocrit and low perfusion oximetry. OrSense's technology, based on proprietary Occlusion Spectroscopy, addresses challenges such as poor peripheral perfusion and motion-induced noise, making it suitable for use in hospitals, outpatient sites, and emergency services. The company’s non-invasive hemoglobin and hematocrit monitor has received CE approval and has been tested on over 4,000 patients across multiple clinical sites in the U.S. and Europe.

novoGI Inc. specializes in the design and development of device-driven solutions for managing gastrointestinal (GI) diseases. The company offers innovative nitinol-based compression anastomosis devices that facilitate the natural reconnection of the intestine after resections, such as those performed in colon cancer treatments. This technology represents a significant advancement in gastrointestinal surgery, as it leverages biological healing processes to enhance patient outcomes. novoGI, originally founded in 1996 as NiTi Surgical Solutions, changed its name in June 2012. The company is headquartered in Atlanta, Georgia, with additional European operations in Paris and research, development, and manufacturing facilities in Netanya, Israel. Its product line includes FDA-cleared and CE-marked disposable tissue closure devices that are designed to support effective healing in patients undergoing colorectal procedures.

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

Mazor Robotics, founded in 2001 and headquartered in Caesarea, Israel, specializes in developing, producing, and marketing medical devices for orthopedic and neurosurgical procedures. The company's primary focus is on surgical robotic-guidance systems that enhance precision and minimize invasiveness during complex surgeries. Their flagship products include the Mazor X and Renaissance systems, which are used extensively in spine surgeries such as fusion, correction of spinal deformities, biopsy collection, tumor excision, and cement augmentations. These systems aim to provide a safer surgical environment for patients, surgeons, and operating room staff by transforming traditional freehand procedures into highly accurate, state-of-the-art operations with better clinical outcomes.

Escape Rescue Systems Ltd., established in 2003, is based in Tel Aviv, Israel. The company specializes in developing and installing innovative systems for high-rise building evacuation, focusing on external evacuation of tenants and rapid deployment of rescue personnel to elevated floors. Their multi-platform rescue system comprises up to five collapsible cabins stored on rooftops, ensuring safety during emergencies while remaining discreet under normal conditions. The company's offerings also include standard systems, life safety features, and fire resistance measures.

GI View Ltd. develops devices for diagnosing and treating gastrointestinal disorders. Its product includes Aer-O-Scope, a disposable, miniaturized, self-propelling, and self-navigating endoscope, which provides video images of the colon inner surface that are displayed on a screen for real time viewing. The company was founded in 2004 and is based in Ramat Gan, Israel.

OrSense Ltd. is a medical device company based in Petah-Tikva, Israel, founded in 1996. The company specializes in developing and marketing non-invasive monitoring technologies for measuring various blood parameters. Its flagship product, the NBM 200 system, enables continuous monitoring of blood hemoglobin levels, oxygen saturation, and pulse rate without the need for invasive procedures. The NBM 200MP further enhances this capability by measuring multiple blood parameters, including hematocrit and low perfusion oximetry. OrSense's technology, based on proprietary Occlusion Spectroscopy, addresses challenges such as poor peripheral perfusion and motion-induced noise, making it suitable for use in hospitals, outpatient sites, and emergency services. The company’s non-invasive hemoglobin and hematocrit monitor has received CE approval and has been tested on over 4,000 patients across multiple clinical sites in the U.S. and Europe.